{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:55:18Z","timestamp":1787165718300,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pediatric pulmonary arterial hypertension (PAH) is a rare and severe disorder characterized by obstructive vascular changes that can lead to right heart failure. The clinical presentation and underlying causes of pediatric PAH differ significantly from those in adults, often involving congenital heart disease and developmental lung disorders, such as bronchopulmonary dysplasia (BPD). Despite advances in treatment, pediatric PAH remains underrecognized globally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed global, regional, and national trends in pediatric PAH from 1990 to 2021 using data from the Global Burden of Disease (GBD) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The findings indicate a stable prevalence rate globally, with a slight increase in the absolute number of cases. Significantly, reductions were observed in both mortality and disability-adjusted life years (DALYs) associated with pediatric PAH, with mortality decreasing by 57.66% and DALYs by 63.59% over the study period, indicating progress in mitigating the disease burden. Substantial regional disparities were identified, with low-income regions, particularly Low Socio-Demographic Index (SDI) areas, experiencing the highest mortality and DALY rates. In contrast, high-middle SDI regions showed the greatest reductions in disease burden. The highest prevalence and burden were observed in South Asia, the Caribbean, and parts of Sub-Saharan Africa, with China, India, and Haiti bearing the greatest national burdens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings highlight the necessity for targeted health interventions, especially in low-resource settings, to improve early diagnosis, intervention, and treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1527281","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T01:26:02Z","timestamp":1751246762000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Burden of pulmonary arterial hypertension in children globally, regionally, and nationally (1990\u20132021): results from the global burden of disease study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lili","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zugen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/cvr\/cvw054","article-title":"Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice","volume":"110","author":"Aliotta","year":"2016","journal-title":"Cardiovasc Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.redox.2015.11.009","article-title":"Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability","volume":"7","author":"Semen","year":"2016","journal-title":"Redox Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s2213-2600(24)00295-9","article-title":"Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"13","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1093\/nar\/gky089","article-title":"Oxidative stress increases M1dG, a major peroxidation-derived DNA adduct, in mitochondrial DNA","volume":"46","author":"Wauchope","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1801916","DOI":"10.1183\/13993003.01916-2018","article-title":"Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management","volume":"53","author":"Rosenzweig","year":"2019","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.07.030","article-title":"Pulmonary hypertension associated to left heart disease: phenotypes and treatment","volume":"129","author":"Madonna","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1601805","DOI":"10.1183\/13993003.01805-2016","article-title":"The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease","volume":"50","author":"Burgstaller","year":"2017","journal-title":"Eur Respir J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/circulationaha.111.026591","article-title":"Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s0140-6736(11)61621-8","article-title":"Clinical features of paediatric pulmonary hypertension: a registry study","volume":"379","author":"Berger","year":"2012","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s2213-2600(22)00097-2","article-title":"Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis","volume":"10","author":"Hoeper","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.1375","article-title":"Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study","volume":"21","author":"Beghetti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2301518","DOI":"10.1183\/13993003.01518-2023","article-title":"Seeing pulmonary hypertension through a paediatric lens: a viewpoint","volume":"63","author":"Agarwal","year":"2024","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e038182","DOI":"10.1136\/bmjopen-2020-038182","article-title":"Screening tools for early identification of children with developmental delay in low- and middle-income countries: a systematic review","volume":"10","author":"Faruk","year":"2020","journal-title":"BMJ Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1542\/pir.2023-006010","article-title":"Pediatric pulmonary hypertension","volume":"45","author":"Morales-Demori","year":"2024","journal-title":"Pediatr Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00080","DOI":"10.1161\/hhf.0000000000000080","article-title":"Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association","volume":"16","author":"Jone","year":"2023","journal-title":"Circ Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/s0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40779-024-00551-6","article-title":"Epidemiological trends of subarachnoid hemorrhage at global, regional, and national level: a trend analysis study from 1990 to 2021","volume":"11","author":"Lv","year":"2024","journal-title":"Mil Med Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2471\/blt.07.045120","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"85","author":"von Elm","year":"2007","journal-title":"Bull World Health Organ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1804492","article-title":"Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016","volume":"379","author":"Feigin","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12968-015-0186-1","article-title":"Non-invasive determination by cardiovascular magnetic resonance of right ventricular-vascular coupling in children and adolescents with pulmonary hypertension","volume":"17","author":"Truong","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/s0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/s1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40272-019-00374-2","article-title":"Drug treatment of pulmonary hypertension in children","volume":"22","author":"Avitabile","year":"2020","journal-title":"Paediatr Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.cjca.2019.10.002","article-title":"Eisenmenger syndrome: a multisystem disorder\u2014do not destabilize the balanced but fragile physiology","volume":"35","author":"Chaix","year":"2019","journal-title":"Can J Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.3390\/ijms24065850","article-title":"New drugs and therapies in pulmonary arterial hypertension","volume":"24","author":"Shah","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/s0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1527281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T01:26:04Z","timestamp":1751246764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1527281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":30,"alternative-id":["10.3389\/fped.2025.1527281"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1527281","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1527281"}}